AUSTIN, Texas – Denosumab (Prolia, Xgeva) carried no increased risk of cardiovascular disease or stroke when compared with zoledronic acid (Reclast, Zometa) to combat osteoporosis, researchers found.
The U.S. Food and Drug Administration (FDA) has issued a black box warning — reserved for the most serious safety issues — for the osteoporosis drug denosumab, sold under the brand name Prolia.
(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone ...
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
This narrative review by an expert International Osteoporosis Foundation (IOF) Working Group highlights an under-recognized bone health risk in women with early-stage, hormone receptor–positive breast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results